Aptevo Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Aptevo Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Aptevo Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Aptevo Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Aptevo Therapeutics Inc (Aptevo) is a clinical-stage biotechnology company focused on the research and development of novel immunotherapy candidates for cancer treatment. It is developing innovative immunotherapy candidates for cancer treatment using its Adaptir and Adaptir-Flex platforms that enable the creation of monospecific, bispecific, and multispecific immunotherapeutic proteins to enhance or regulate immune responses. Aptevo's major products include clinical candidates mipletamig and ALG.APV-527, as well as several preclinical candidates, including APVO603, a dual agonist that targets both 4-1BB and OX40; APVO442, which is designed for prostate cancer; and APVO711, which stimulates CD40 while inhibiting the PD-1/PD-L1 pathway. It’s products are designed for applications in oncology, targeting various forms of cancer. The company collaborates with partners such as Alligator Bioscience for the development of certain therapies. Aptevo is headquartered in Seattle, Washington, the US.
Headquarters
United States of America
Address
Suite 1050, 2401 4th Avenue, Seattle, Washington, 98121
Website
aptevotherapeutics.com
Telephone
1 206 8380500
No of Employees
33
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
APVO (NASD)
EPS
XYZ
Net Income (2024)
XYZ
-7.6%
(2024 vs 2023)
Market Cap*
$5.6M
Net Profit Margin (2021)
XYZ
0.0%
(2024 vs 2023)
* As of and is in US$
Aptevo Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline: |
| Mipletamig (APVO436): Acute Myeloid Leukemia (AML) |
| ALG.APV-527: Solid Tumors |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Official Trials/Tests | In August, the company initiated its Phase 1b/2 dose optimization trial, RAINIER, as part of its ongoing program to evaluate APVO436 in combination with venetoclax + azacitidine for frontline patients with acute myeloid leukemia. |
| 2022 | Plans/Strategy | In May, the company has announced that it has initiated the expansion phase of lead anti-leukemia drug candidate, APVO436. |
| 2020 | New Products/Services | In December, the company launched its second platform technology, ADAPTIR-FLEX, a bispecific platform technology to include a new multi-specific platform technology and it also introduced a new bispecific candidate, APVO442, that uses ADAPTIR-FLEX platform technology. |
Competitor Comparison
| Key Parameters | Aptevo Therapeutics Inc | AbbVie Inc | Bristol-Myers Squibb Co | Amgen Inc | Gilead Sciences Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Seattle | North Chicago | Princeton | Thousand Oaks | Foster City |
| State/Province | Washington | Illinois | New Jersey | California | California |
| No. of Employees | 33 | 57,000 | 32,500 | 31,500 | 17,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Marvin L. White | Chairman | Executive Board | 2026 | 64 |
| Jeffrey G. Lamothe | Chief Executive Officer; Director; President | Executive Board | 2026 | 60 |
| Daphne Taylor | Chief Financial Officer; Senior Vice President | Senior Management | 2023 | 60 |
| Dirk Huebner, M.D. | Chief Medical Officer | Senior Management | - | - |
| Mary J. Janatpour, PhD | Senior Vice President; Chief Scientific Officer | Senior Management | 2026 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer